US-based Illumina has debuted an updated version of its VeriSeq NIPT Analysis Software for clinical laboratories in the European Union (EU), to perform optimised data analysis for non-invasive prenatal testing (NIPT).
The new version of the analysis software is equipped with a new method to process samples and is developed for larger batches of 48 samples, expanding the current 16 samples.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The validated CE-IVD marked analysis software analyses sequencing data for use in NIPT by utilising a whole-genome sequencing (WGS)-based method, which involves analysis of trisomy 13, 18, 21, sex chromosome aneuploidies.
Illumina Reproductive and Genetic Health vice-president and general manager Jeff Hawkins said: “The update to the VeriSeq NIPT Analysis Software is another important milestone towards providing a more complete high-quality NIPT solution to our laboratory partners in the EU.
“With this software, Illumina is enabling more clinical laboratories to implement NIPT testing efficiently and affordably in-house, increasing overall workflow efficiency and reducing the costs of testing.”
The software filters and aligns WGS sequencing reads to a reference genome, prior to using counting-based algorithm to identify over- or under- represented test chromosomes, resulting in a normalised chromosome value (NCV) for the test chromosome.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe firm has applied for CE marking of the upgraded software, which introduces a paired-end sequencing data method.
It identifies and differentes fetal aneuploidy status for chromosomes 21, 18, 13, X and Y through sequencing data analysis generated from cell-free DNA fragments, which are isolated from maternal peripheral whole blood specimens in pregnant women of at least 10 weeks gestation.
